


HBM Healthcare Investments invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and actively manages an international portfolio of promising companies.

Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).


Currency allocation of assets ¹⁾

Emphasis on US dollar investments.




Allocation of assets ¹⁾

Mainly invested in private companies or in companies originating from the private companies portfolio.



Development phase of portfolio companies³⁾

Mainly invested in revenue generating companies or in companies with products at an advanced stage of development.



Investments by continents³⁾


International portfolio with its main focus on North America.



1) Total assets (net of liability to Subsidiary) as at 31.12.2018: CHF 1 286 million.

Therapeutic area of the lead product of portfolio companies ³⁾

Broadly diversified areas of activity.



2) Thereof about 7 percent is hedged.

3) Total investments as at 31.12.2018: CHF 1103 million.

Key Figures		31.12.2018	31.3.2018	31.3.2017	restated 31.3.2016	restated 31.3.2015
Net assets	CHF million	1190.5	1 157.9	1 095.8	1 034.8	1 086.6
Investments in private companies and funds		479.2	413.9	274.3	299.5	273.4
Investments in public companies		623.4	750.0	813.6	677.0	748.1
Cash and cash equivalents (net of liability from market hedging)		156.9	72.4	77.0	104.8	76.9
Net result for the period	CHF million	81.3	115.9	136.8	23.8	257.5
Basic earnings per share	CHF	11.69	16.55	18.96	3.11	32.47
Net asset value (NAV) per share	CHF	171.12	166.43	155.09	139.41	140.12
Share price	CHF	155.40	144.00	111.40	99.45	108.00
Discount	%	-9.2	-13.5	-28.2	-28.7	-22.9
Distribution per share	CHF		7.00	5.80	5.50	5.50
Distribution yield	%		4.9	5.2	5.1	5.1
Shares issued	Registered shares (m)	7.0	7.0	7.3	7.7	8.0
Shares outstanding	Registered shares (m)	7.0	7.0	7.1	7.4	7.8

Performance (including distributions)		2018/2019 (9 months)	2017/2018	2016/2017	restated 2015/2016	restated 2014/2015
Net asset value (NAV)	%	7.0	11.1	15.2	3.4	31.6
Registered share HBMN	%	12.8	34.5	17.5	-2.8	47.0

Net asset value (NAV) and share price versus MSCI World Health Care Index in CHF, indexed (12.7.2001 = 100)



HBM Healthcare Investments withstood the market correction relatively well thanks to the partial hedge that we had in place, and the growth in the value of the portfolio of private companies. Indeed, at 7.4 percent, net asset value (NAV) per share contracted much less than the comparable indices during the guarter under review, for which HBM Healthcare Investments reported a loss of CHF 96 million. However, the Company is still showing a profit of CHF 81 million for the first nine months of the current 2018/2019 financial year, owing to the high earnings of the first half. NAV rose by 7.0 percent during this period, while the share price advanced by as much as 12.8 percent. In addition to a number of follow-on financing rounds, the quarter under review saw new investments in four private companies. The market hedge of the public portfolio was reduced considerably towards the end of the quarter.

Dear Shareholders

HBM Healthcare Investments withstood the heavy price correction on the financial markets during Q4 2018 relatively well. Indeed, with a decline of 7.4 percent, net asset value (NAV) per share contracted much less than comparable indices. On the one hand, the partial market hedge and the timely realisation of portfolio holdings to generate liquidity absorbed some of the fall in our public companies' share prices. Another factor was growth in the value of our private companies. Overall, HBM Healthcare Investments made a loss of CHF 96 million during the quarter under review.

Notwithstanding the negative result for the most recent quarter, the Company is showing a profit of CHF 81 million for the first nine months of the 2018/2019 financial year, with NAV up by 7.0 percent. The share price advanced by 12.8 percent during the same period.

Positive trend among private companies

A number of firms in the portfolio of private companies performed very well indeed:

Neurelis submitted an application for regulatory approval to the US FDA for VALTOCO[™], a nasal spray for the treatment of acute epileptic seizures. Approval is expected in 2019. In addition, in November the company concluded a USD 55 million financing round with CMS Medical Ventures, as a new investor. HBM Healthcare Investments contributed USD 9.5 million to this financing arrangement, which led to the value of the holding to be upgraded by just under CHF 20 million.

In December, 1mg – the leading digital healthcare platform in India – completed a financing round worth the equivalent of around CHF 70 million that was led by a Swiss investors group. HBM Healthcare Investments itself contributed CHF 5 million. Once again, this financing round resulted in the upward revaluation of the company, increasing the value of our existing investment by around CHF 8 million.

Meanwhile, last year Swiss company Amicus concluded new agreements with 15 companies to license, market or represent products in central and eastern Europe. This rapidly-expanding firm generated sales of more than EUR 70 million in 2018, and is on course to raise turnover to over EUR 100 million in 2019. Our holding in Amicus continues to be valued at cost price in our portfolio.

Shortly before the end of 2018, Harmony Biosciences applied to the FDA for regulatory approval for Pitolisant for the US market. Pitolisant is a drug that is used to treat narcolepsy and cataplexy, and is already approved in Europe.

Cathay Industrial Biotech, the Chinese manufacturer of organically based materials from renewable resources, completed the first phase of construction of a new production facility in Xinjiang, which is now operational. The company is now planning to invest a further USD 500 million in a second phase of construction to double its production capacity in Xinjiang.

New investments in private companies

In addition to the follow-on financing rounds referred to above, the quarter under review brought new investments in four private companies:

- > A total of CHF 15 million is being invested in two companies set up by the former scientific head and cofounder of Brahms, a very successful former HBM Healthcare Investments portfolio company. Both companies are based in Henningsdorf, Germany.
 - Diagnostics firm Sphingotec develops and markets the innovative penKid[®] and bio-ADM[®] biomarkers to predict, diagnose and monitor the treatment of acute kidney injuries, heart failure, and septic shock. An initial EUR 4.5 million tranche of a total of EUR 9 million has been paid in.
 - Andrenomed is conducting a phase II trial to test the adrecizumab antibody in the treatment of patients with septic shock. EUR 0.3 million in share capital has been paid in to date, with three further tranches to follow from early 2019 onwards. Andrenomed will receive a total of EUR 6 million.
- > TP Therapeutics, an oncology firm based in San Diego, USA, received USD 10 million. In its most advanced development programme, the company is conducting a phase I/II trial of a kinase inhibitor for the targeted treatment of lung cancer.
- > EUR 7 million is being invested in Danish company Galecto Biotech, with the first tranche of EUR 3.2 million – already paid in. Galecto is conducting clinical trials of a compound to treat idiopathic pulmonary fibrosis.

Outlook

The accelerated price drop on the financial markets was followed after Christmas by a counterreaction which continued into the first few weeks of the new year. The lower level of valuations has also prompted resurgent M&A activity in the healthcare sector in recent weeks, with GSK acquiring Tesaro, Bristol-Myers Squibb purchasing Celgene, and Eli Lilly buying Loxo Oncology. The buyers offered high purchase premiums in each case. The takeovers have restored market sentiment in the healthcare sector somewhat, which should benefit HBM Healthcare Investments.

That said, financial market volatility can be expected to remain high as we enter the new year. The primary reasons for this are political developments, signs that the global economy is slowing down, and the tighter monetary policy that is already in place in the United States and will affect Europe in the future. We will monitor these developments closely and, when necessary, increase the market hedge on a portion of our public portfolio once again – having closed out around two thirds of it owing to the sharp drop in share prices during the fourth quarter.

With a global portfolio of high quality private and public companies, as well as plenty of liquidity, HBM Healthcare Investments remains very well positioned even in the current market climate. We firmly believe that our investment strategy and our carefully crafted portfolio will continue to generate attractive added value for you, our valued shareholders, in the years to come.

Dr Andreas Wicki CEO

Then

Erwin Troxler CFO

Balance sheet (CHF 000)	Notes 31.12.2018	31.3.2018
Assets		
Current assets		
Cash and cash equivalents	4982	6 522
Receivables	37	37
Total current assets	5019	6 559
Non-current assets		
Investment in subsidiary	(3) 1 338 482	1 253 924
Total non-current assets	1 338 482	1 253 924
Total assets	1 343 501	1 260 483
Liabilities		
Current liabilities		
Liability to subsidiary	52000	0
Liability from performance fee	0	1 018
Other liabilities	1619	2 333
Total current liabilities	53619	3 3 5 1
Non-current liabilities		
Financial liabilities	(4) 99360	99 236
Total non-current liabilities	99360	99 236
Shareholders' equity		
Share capital	(5.1) 396720	411 840
Treasury shares	(5.2) -402	- 10 048
Capital reserve	(5.1) 142 093	185 318
Retained earnings	652111	570 786
Total shareholders' equity	1 190 522	1 157 896
Total liabilities and shareholders' equity	1 343 501	1 260 483
Number of outstanding shares (in 000)	6 957	6 957
Net asset value (NAV) per share (CHF)	171.12	166.43

Result from investment activities Personnel expenses Other operating expenses Result before interest and taxes Financial expenses Financial income Income taxes Net result for the period	Notes	Quarter ended 31,12,2018	Quarter ended 31.12.2017	9-month period ended 31.12.2018	9-month period ended 31 12 2017
Net change in value of investment in subsidiary	(3)	-94 473	73 153	84 558	88761
Result from investment activities		-94 473	73 153	84 558	88 761
Personnel expenses		-204	-238	-614	-641
Other operating expenses		-312	-248	-790	-640
Result before interest and taxes		- 94 989	72 667	83 154	87 480
Financial expenses	(4)	-604	-620	-1830	-1834
Financial income		1	1	1	1
Income taxes		0	0	0	0
Net result for the period		-95 592	72 048	81 325	85 647
Comprehensive result		- 95 592	72 048	81 325	85647
Number of outstanding shares, time-weighted (in 000)		6957	6981	6 957	7014
Basic earnings per share (CHF)		-13.74	10.32	11.69	12.21

As the Company does not have options or similar instruments outstanding, diluted earnings per share are identical to basic earnings per share.

Statement of cash flows for the period 1 April to 31 December (CHF 000)	9-month period ended 31.12.2018	9-month period ended 31.12.2017
Other expenses paid (personnel and other operating expenses)	-2573	-2876
Net cash flow from operating activities	-2573	-2876
Interest payments paid	-2269	-2273
Loan from subsidiary	52 000	60 000
Cash distribution from capital reserve	-38264	-40783
Par value repayment	- 10 435	0
Purchase of treasury shares	0	-12484
Net cash flow from financing activities	1 032	4 460
Currency translation differences	1	1
Net change in cash and cash equivalents	-1 540	1 585
Cash and cash equivalents at beginning of period	6 522	6115
Cash and cash equivalents at end of period	4 982	7 700

Statement of changes in equity (CHF 000)	Share capital	Treasury shares	Capital reserve	Retained earnings	Total shareholders' equity
Balance 31 March 2017	427 050	-23563	237 362	454 912	1 095 761
Comprehensive result				85647	85647
Purchase of treasury shares		-12376	·····		-12376
Distribution from capital reserve (30.6.2017)	••••••		-40783		-40783
Capital reduction (14.9.2017)	-15210	26 47 1	- 11 261		0
Balance 31 December 2017	411 840	-9468	185 318	540 559	1 1 28 2 49
Comprehensive result				30 227	30 227
Purchase of treasury shares		-580			-580
Balance 31 March 2018	411 840	-10048	185 318	570 786	1 157 896
Comprehensive result				81 325	81 325
Purchase of treasury shares	••••••	0		••••••	0
Distribution from capital reserve (29.6.2018)			-38264	••••••	- 38 264
Capital reduction (10.9.2018)	-4680	9646	-4966		0
Par value repayment (21.9.2018)	- 10 440		5		- 10 435
Balance 31 December 2018	396 720	-402	142 093	652111	1 190 522

General Statements

1. Information about the Company and its business

HBM Healthcare Investments Ltd (HBM Healthcare or Company) is a SIX Swiss Exchange-listed holding company domiciled at Bundesplatz 1, Zug (Switzerland). The purpose of the Company is the acquisition, holding and sale of positions in other companies as well as the management and financing of such positions in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas.

2. Accounting policies

The condensed interim financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) IAS 34 on Interim Financial Reporting, and the provisions of the SIX Swiss Exchange Additional Rules on the Listing of Investment Companies. These interim financial statements should be read in conjunction with the Group Financial Statements for the financial year ended 31 March 2018, as they provide an update to the latest full financial report.

In preparing the interim financial statements, the same accounting policies and methods of computation have been applied as in the preparation of the annual financial statements as at 31 March 2018. A summary of the new and revised IFRS/IAS standards and interpretations effective in the year under review is provided on pages 62 and 63 of the Group Financial Statements of the 2017/2018 Annual Report. The newly applied standards and interpretations had no material impact on the Group's accounting policies, overall results or financial position.

The following exchange rates were used in the preparation of the financial statements:

Exchange rates (CHF)	31.12.2018	31.3.2018
CAD	0.7210	0.7395
DKK	0.1510	0.1577
EUR	1.1274	1.1757
GBP	1.2540	1.3370
INR	0.0141	0.0146
SEK	0.1111	0.1144
USD	0.9832	0.9540

Notes to the Balance Sheet and Statement of Income

3. Investment in Subsidiary

The fair value of the investment in the Subsidiary HBM Healthcare Investments (Cayman) Ltd developed as follows in the period under review:

9-month	9-month
period ended	period ended
Development fair value investment (CHF 000) 31.12.2018	31.12.2017
Fair value at the beginning of period 1253 924	1 192 834
Change in value, gross 84558	88 761
Fair value at the end of period1 338 482	1 281 595

Net assets of the investment in the Subsidiary comprised the following as at the balance sheet date:

Composition net assets (CHF 000)	31.12.2018	31.3.2018	31.12.2017
Cash and cash equivalents	197 673	213 551	240 080
Receivables	416	393	235
Loan to parent company	52 000	0	60 000
Investments			
Private companies	351 409	288 365	229093
Funds	127 769	125 579	123586
Public companies	623 387	749 960	740613
Shares of parent company	14 261	7 403	10201
Financial instruments	320	3 1 2 1	1 995
Other financial assets	31 131	29740	31 098
Total assets	1 398 366	1 418 112	1 436 901
Financial instruments	-45714	-147 628	-142874
Liability from performance fee	-11360	- 15 942	-11615
Other current liabilities	-2810	-618	-817
Total net assets at fair value	1 338 482	1 253 924	1 281 595

During the reporting period, the net assets of the investment in the Subsidiary have developed as follows:

Financial result Change in value, gross	- 13 063 - 11 360 - 907 44 84 558	- 10 374 - 11 615 - 1 064 12 88 761
Financial result	-11360 -907 44	-1064 12
	-11360 -907	
Personnel and other operating expenses		- 10374 - 11615
Performance fee	- 13063	-10374
Management fee	10.000	
Result from investing activities	109 844	111 802
Net result from shares of parent company	1 229	1 317
Net result from other financial assets	5967	-1449
Net result from financial instruments	13 407	- 30 033
Dividend income	482	108
Net result on investments	88759	141 859
	9-month od ended 1.12.2018	9-month period ended 31.12.2017

For details of individual items of net assets (balance and change) please refer to the following explanations.

3.1 Investments

During the reporting period, the investments held by the Subsidiary comprised the following and they performed as follows:

	Private		Public	Total
Development of investments (CHF 000)	companies	Funds	companies	investments
Fair value 31 March 2018	288 365	125579	749 960	1 163 904
Reclassification owing to IPO (Aptinyx)	-6201	0	6 201	0
Reclassification owing to IPO (Y-mAbs Therapeutics)	- 22 176	0	22 176	0
Fair value 31 March 2018 (after reclassification)	259 988	125 579	778 337	1 163 904
Purchases	85879	15941	346 610	448 430
Sales	-37 894	-15202	- 545 432	- 598 528
Realised gains	25 520	78	201 585	227 183
Realised losses	-5 525	-379	-87682	-93 586
Changes in unrealised gains/losses	23 441	1 752	-70 031	-44 838
Net result on investments	43 436	1 451	43 872	88759
Fair value 31 December 2018	351 409	127 769	623 387	1 102 565

Details on investments can be found on pages 14 to 16.

Private companies	Domicile	Investment currency	- Amount disbursed 31.3.2018	Changes in reporting period	Amount disbursed 31.12.2018	Fair value 31.12.2018	Ownership 31.12.2018	Fair value 31.12.2018	Fair value 31.3.2018
		IC	IC million	IC million	IC million	IC million	%	CHF 000	CHF 000
Cathay Industrial Biotech	CN	USD	28.0		28.0	91.5	7.9	89 964	87 292
Neurelis	US	USD	8.3	9.5	17.8	37.7	15.0	37 067	7 870
Harmony Biosciences	US	USD	30.0		30.0	32.6	8.1	32 06 1	31 109
Amicus	СН	EUR	20.0		20.0	20.0	29.0	22 549	23514
1mg	IN	INR	515.7	357.1	872.8	1 452.4	12.5	20 468	7 543
SAI Life Sciences	IN	INR	256.4		256.4	1 151.4	5.8	16 226	6019
Jianke Pharmaceutical	CN	USD	0.0	14.9	14.9	14.9	3.4	14625	0
Westmed Holding	US	USD	7.0		7.0	12.4	25.2	12 225	11862
Vascular Dynamics	US	USD	10.0	0.9	10.9	10.9	13.1	10730	9 505
TP Therapeutics	US	USD	0.0	10.0	10.0	10.0	3.3	9832	0
FarmaLatam	PA	USD	7.7	1.2	8.9	9.9	69.9	9780	7 320
ConnectRN	US	USD	1.5	2.5	4.0	6.6	18.1	6 499	1 431
Sphingotec	DE	EUR	0.0	4.5	4.5	4.5	7.1	5078	0
Cardialen	US	USD	0.0	5.0	5.0	5.0	17.8	4916	0
Galera Therapeutics	US	USD	0.0	5.0	5.0	5.0	2.0	4916	0
Forbius (Formation Biologics	s) CA	CAD	6.5	••••	6.5	6.5	10.0	4651	4771
Valcare	US	USD	3.5	0.8	4.3	4.3	7.4	4 204	3 3 3 9
Sublimity Therapeutics	ΙE	EUR	0.0	3.5	3.5	3.5	7.1	3 999	0
Vitaeris	CA	USD	3.0		3.0	4.0	18.9	3 933	3816
Corvidia Therapeutics	US	USD	0.0	4.0	4.0	4.0	3.0	3 933	0
Galecto Biotech	DK	EUR	0.0	3.2	3.2	3.2	4.3	3 587	0
Shriji Polymers	IN	INR	201.0	••••	201.0	216.2	2.8	3047	3 163
Cure Everlife Holdings	MU	USD	0.0	3.0	3.0	3.0	7.8	2 950	0
Everest Medicines	CN	USD	0.0	3.0	3.0	3.0	1.0	2 950	0
Shape Memory Medical	US	USD	3.0	••••	3.0	3.0	10.9	2 950	2862
Complexa	US	USD	2.9	••••	2.9	2.9	4.1	2 856	2771
Amphora Medical	US	USD	2.2	0.4	2.6	2.6	5.5	2519	2074
BaseHealth	US	USD	2.5	••••	2.5	2.5	6.3	2 4 5 8	2385
Nuance Biotech	CN	USD	0.0	2.0	2.0	2.0	2.1	1 966	0
iTeos Therapeutics	BE	EUR	0.0	1.6	1.6	1.6	1.8	1818	0
Adrenomed	DE	EUR	0.0	0.3	0.3	0.3		386	0
Iconic Therapeutics ¹⁾	US	USD	7.5	•••••	7.5	0.0	7.1	0	1789
TandemLife (Cardiac Assist)	²⁾ US	USD	4.4	-4.4	0.0	0.0	0.0	0	31148
Others								6 266	8 405
Total private companies								351 409	259 988

1) This investment was fully written off during the reporting period.

2) The company was acquired during the last financial year. The transaction was completed in the current reporting period on 4 April 2018.

Funds	Invest- ment Total currency commitment	Payments in reporting period	Repayments in reporting period	Cumulative payments 31.12.2018	Cumulative repayments 31.12.2018	Fair value 31.12.2018	Fair value 31.12.2018	Fair value 31.3.2018	
	IC	IC million	IC million	IC million	IC million	IC million	IC million	CHF 000	CHF 000
HBM BioCapital II ¹⁾	EUR	42.0	4.2	5.6	41.2	9.2	22.1	24 901	30 585
WuXi Healthcare Ventures II	USD	20.0	2.8		15.8	0.6	19.9	19580	12974
MedFocus Fund II	USD	26.0		******	16.0	15.0	18.9	18 555	17971
6 Dimensions Capital	USD	25.0	3.2	0.1	16.2	0.1	15.3	15059	12243
HBM Genomics	USD	15.0	2.8	•••••••••••••••••••	11.7	0.0	11.2	10 989	8137
Tata Capital HBM Fund I	USD	10.0	0.2	4.2	9.3	4.7	7.9	7 7 4 6	9094
Hatteras Venture Partners III	USD	10.0		•••••••••••••••••••	10.0	2.0	7.7	7 527	8 2 5 0
BioMedInvest II	CHF	10.0		1.2	10.0	3.0	7.3	7 340	8840
BioMedInvest I	CHF	26.0		1.0	26.0	25.6	5.9	5 902	6994
Galen Partners V	USD	10.0	0.1	1.2	10.4	8.8	5.2	5 1 5 9	5168
BioVeda China IV	USD	5.0	1.4	••••••••••••••••••••••••	1.4	0.0	1.3	1 289	0
Nordic Biotech	DKK	31.0	••••	••••••••••••••••••••••••	31.0	221.7	7.0	1 030	2781
C-Bridge Capital IV	USD	10.0	0.9	0.1	0.9	0.1	0.7	708	0
Others								1 984	2542
Total funds								127 769	125579

 The fair value of EUR 22.1 million takes into account the fund's cumulative management fees of EUR 5.1 million. This amount has been reimbursed in full to HBM Healthcare so that fees are not levied twice.

	1	-	Channes	Ohannaa	Delever	Ob a second a second	0	E da contra d	E da contra
Public companies	Investment currency	Balance 31.3.2018	Changes 9 months	Changes 3 months	Balance 31.12.2018	Share price 31.12.2018	0wnership 31.12.2018	Fair value 31.12.2018	Fair value 31.3.2018
	IC	Number of shares	Number of shares	Number of shares	Number of shares	IC	%	CHF 000	CHF 000
Y-mAbs Therapeutics ^{1) P)}	USD	2 486 095	328 399	-261601	2814494	20.34	8.2	56 285	22176
Vectura Group	GBP	63 002 869	-15185858	-4078579	47 817 011	0.70	7.2	41 973	65410
Pacira Pharmaceuticals ^{P)}	USD	1 100 000	-149738	-149738	950 262	43.02	2.3	40 194	32689
Galapagos	EUR	300 000	-7858	-17 935	292 142	80.56	0.5	26 534	28676
Tesaro	USD	250 000	82 500	102 500	332 500	74.25	0.6	24 273	13628
Principia Biopharma ^{1) P)}	USD	0	833 923	-425 000	833 923	27.39	3.5	22 457	0010
mmunomedics	USD	1 400 000	158014	360 000	1 558 014	14.27	0.8	21 859	19513
Jltragenyx Pharmaceutical	USD	500 000	0	254 499	500 000	43.48	1.0	21 375	24322
Esperion Therapeutics	USD	400 000	72257	0	472 257	46.00	1.8	21 359	27 601
Alnylam Pharmaceuticals	USD	0	257 813	70 000	257 813	72.91	0.3	18 481	
Zogenix	USD	400 000	113219	11 009	513219	36.46	1.2	18 398	15 283
Argenx	EUR	250 000	-60 000	0	190 000	85.20	0.5	18 251	19164
Argenx (ADR)	USD	250 542	-60542	-30 000	190 000	96.07	0.5	17 947	19 227
DbsEva (ADS) ^{P)}	USD	2313330	-926732	-37 800	1 386 598	12.66	3.2	17 259	29782
A Pharmaceuticals	USD	750 000	175000	-97 583	925 000	12.00	3.2	16 552	3799
AnaptysBio ^{P)}	USD	200 000	46 175	16 175	246 175	63.79	0.9	15 440	19858
Arena Pharmaceuticals	USD	250 000	115000	115 000	365 000	38.95	0.3	13 978	9421
Retrophin	USD	433 952	153197	37 000	587 149	22.63	1.4	13 064	9257
Aptinyx ^{1) P)}	USD	790 873	0	0	790 873	16.54	2.4	12 861	6 2 0 1
nflarx	USD	0	344 594	344 594	344 594	36.37	1.3	12 322	0201
Acadia Pharmaceuticals	USD	700 000	0	0	700 000	16.17	0.5	11 129	15005
Amicus Therapeutics	USD	844784	214277	0	1 059 061	9.58	0.5	9975	12121
Divis Laboratories	INR	608 000	-135700	- 98 400	472 300	1 482.65	0.0	9868	9695
licox	EUR	1 673 304	- 133700	- 30 400	1673304	5.01	5.6	9452	17 844
Amarin (ADR)	USD	0	700 000	700 000	700 000	13.61	0.2	9367	17044
Beigene	HKD	0	700 000	000000	700 000	84.10	0.2	7 390	0
Beigene (ADR)	USD	0	50 000	20 000	50 000	140.26	0.1	6 895	0
Coherus Biosciences	USD	577 442	240 000	240 000	817 442	9.05	1.2	7 274	6 0 8 7
Albireo Pharma	USD	200 000	100 000	74112	300 000	24.53	2.5	7 2 3 5	6214
Iniqure	USD	200 000	250 000	50 000	250 000	24.55	0.7	7 235	0214
pring Bank Pharmaceuticals	USD	258736	400 000	0	658736	10.39	4.0	6729	3796
	CHF		••••••••••••••••••••••••••••	·····	• • • • • • • • • • • • • • • • • • • •		•••••••••••••••••••••••••••••••••••••••		
dorsia	USD	0	400 000	0	400 000	16.22 22.62	0.3	6 488	0
Assembly Biosciences		0	290727	90 000	290727		1.1	6 466	0
Reata Pharmaceuticals	USD	0	115417	55 000	115417	56.10	0.5	6 366	
Arrowhead Pharmaceuticals	USD	0	500 000	470 000	500 000	12.42	0.5	6 106	0
Iubilant Life Sciences	INR	0	459406	120.000	459 406	710.60	0.3	4601	0
lansa Medical	SEK	0	130 000	130 000	130 000	276.80	0.3	3 9 9 6	11 100
Paratek Pharmaceuticals	USD	895 000	- 187 552	-44 691	707 448	5.13	2.2	3 568	11100
)ynavax Technologies	USD	0	375000	0 E 100	375 000	9.15	0.6	3 374	0
ubius Therapeutics	USD	0	207 592	-5100	207 592	16.08	0.3	3 282	0
Kenon Pharmaceuticals ^{P)}	USD	0	521789	0	521 789	6.31	2.1	3 2 3 7	C
ARMO BioSciences ^{P)}	USD	1 591 540	-1591540	0	0	n/a	0.0	0	56801
veXis	USD	100 000	-100000	0	0	n/a	0.0	0	11790
Others								32 643	261877
otal public companies								623 387	778337

P) The position originates from the private companies portfolio.
1) The companies went public on NASDAQ in June and September 2018 respectively. The investments were listed under private companies in previous reports.

3.2 Financial instruments

The Subsidiary buys and sells derivative financial instruments in the course of its ordinary business activities and as part of its risk management. The following positions were held as at the balance sheet date:

Holdings of financial instruments (CHF 000)	31.12.2018	31.3.2018
Other financial instruments		
Purchased call and put options	320	3121
Total long financial instruments	320	3121
Market hedging		
Sale of Exchange Traded Funds (ETFs)	45 714	140 532
Other financial instruments		
Sale of shares	0	7 0 9 6
Total short financial instruments	45 714	147628

As at the balance sheet date, a partial hedge of the general market risk derived from public investments was in place. Worth CHF 45.7 million, it consisted of the short sale of 0.65 million units of the SPDR S&P Biotech ETF (Exchange Traded Fund).

The following gains and losses resulted from derivatives transactions conducted during the period under review:

	9-month	9-month
Income from financial instruments (CHF 000)	period ended	period ended
	31.12.2018	31.12.2017
Gains from market hedging transactions	13 206	0
Gains from other financial instruments	2513	2 158
Total gains from financial instruments	15719	2158
Losses from currency hedging transactions	0	-1973
Losses from market hedging transactions	0	-25941
Losses from other financial instruments	-2312	-4277
Total losses from financial instruments	-2312	- 32 191
Net result from financial instruments	13407	- 30 033

3.3 Other financial assets

Other financial assets consist primarily of contractual claims to purchase price payments from earlier trade sales that are contingent on the achievement of defined targets (milestone payments). These claims are recognised at fair value through profit and loss by applying a probability-weighted valuation approach based on the assessment of the likelihood of attaining the underlying targets. These claims are discounted over time at a discount rate of 11.0 percent (previous year: 11.0 percent) in the Group Financial Statements. The valuation measures applied refer to commonly used industry statistics as well as own guidelines and estimates. Of the total book value as at 31 December 2018, CHF 31.1 million were carried as other financial assets (claims from investments held directly by HBM Healthcare). An additional CHF 2.9 million are reported under "Investments - Other private companies" (claims from investments held indirectly via HBM BioCapital I).

If the companies concerned are successful, these contractual claims could result in future payments which are many times the reported book value.

The following summary shows the value carried in the balance sheet compared with the potential cash flows:

Balance sheet value and potential cash flows (CHF million)	Book value 31.12.2018	Cash flows minimum	Cash flows maximum	Expected period of payment
mtm laboratories	13.3	0.8	25.9	2020
TandemLife (Cardiac Assist)	8.4	4.6	11.7	2019-2021
Nereus ¹⁾	6.2	0.0	20.4	2019-2025
True North Therapeutics	5.8	1.3	13.1	2019-2020
Interventional Spine	0.3	0.0	4.1	2019
Tripex (former Mpex) ²⁾	0.0	0.0	8.7	from 2019 onwards
Total	34.0	6.7	>83.9	

1) The valuation is based on a previous asset sale to Triphase Accelerator and on the share price of BeyondSpring, and thus depends on the share price development. **2)** Not including any revenue-sharing agreement. The potential return may be higher than this figure.

3.4 Management fee and performance fee The management fee due to HBM Partners amounts to 0.75 percent per year of the Company's assets plus 0.75 percent per year of its market capitalisation, payable quarterly at the beginning of a quarter. In the 9-month period up to the end of September 2018, HBM Partners was paid CHF 13.1 million (previous year: CHF 10.4 million).

A provision for a performance fee of CHF 11.4 million was made during the reporting period

(previous year: CHF 11.6 million) because net assets as at the balance sheet date exceeded the highest net assets (high water mark) used as the calculation basis for the last performance fee payment. The high water mark for all outstanding shares is CHF 161.87 (adjusted for any dividends and capital repayments to shareholders). The cut-off date for the payment of any performance fee is 31 March of a financial year.

3.5 Off-balance-sheet commitments

The Subsidiary had the following investment commitments as at the balance sheet date:

Investment commitments (CHF 000)	31.12.2018	31.3.2018
HBM BioCapital I+II	1 193	6143
Other funds	39 465	30 0 50
Private companies	40 363	9946
Total investment commitments	81 021	46139

4. Non-current financial liabilities

The following non-current financial liabilities were outstanding as at the balance sheet date: two straight bond tranches with a par value of CHF 50 million each, coupons of 2.0 and 2.5 percent and maturing on 10 July 2021 and 10 July 2023 respectively; to be redeemed at 100 percent of par value.

The bond tranches could become due for early repayment, if the outstanding investment commitments to investment funds exceed the amount of CHF 100 million or the fair value of all investments in public portfolio companies plus cash and cash equivalents is less than two and a half times the amount of the interest-bearing financial liabilities.

The straight bonds are carried at amortised cost, subject to the effective interest method. The difference between the net proceeds (after the deduction of CHF 1.2 million in transaction costs) and the amount repayable when the bond falls due for redemption is amortised over the term of the bonds and charged to financial expenses along with the interest that has been paid. The effective interest rates are 2.22 and 2.67 percent, respectively.

5. Shareholders' equity

5.1 Share capital and capital reserve As at the balance sheet date, the Company's share capital stood at CHF 396.72 million, divided into 6960000 registered shares at a par value of CHF 57.00 each. At the Shareholders' Meeting of 25 June 2018, the decision was made to cancel 80000 treasury shares. The capital reduction was entered in the Commercial Register of the Canton of Zug on 10 September 2018.

Along with the capital reduction, the Shareholders' Meeting also approved a withholding tax-exempt distribution from the capital reserve of CHF 5.50 per share, which was paid on 29 June 2018. Further, the Shareholders' Meeting approved an additional cash distribution of CHF 1.50 per share by means of a par value reduction. The cash payment to Shareholders was made on 21 September 2018 after the expiration of the legal deadlines.

5.2 Treasury shares

The Shareholders' Meeting of 24 June 2016 authorised the Board of Directors to repurchase a maximum of 730000 of the Company's own shares via a second trading line. The aim of this share buy-back programme is to cancel the shares as part of a capital reduction. It will be completed no later than 23 June 2019 ("2016 share buy-back programme"). The programme started on 6 October 2016. Under this share buy-back programme a total of 243910 of the Company's own shares have been repurchased up to the balance sheet date.

The Company holds 2910 of its own shares (as at 31 March 2018: 82910) as at the balance sheet date. In the 9-month period, none of the Company's own shares were acquired (previous year: 104210 at CHF 118.76).

Holdings from second trading line (number of own shares)				
Beginning of period 1 April 2018	82 910			
Acquired via second trading line under share buy-back programme	0			
Capital reduction owing to cancellation of own shares	- 80 000			
End of period 31 December 2018	2910			

In addition, the subsidiary HBM Healthcare Investments (Cayman) Ltd holds 91772 treasury shares (as at 31 March 2018: 51411), acquired via the regular trading line. During the 9-month period, the Subsidiary acquired a total of 227919 treasury shares via the regular trading line at an average price of CHF 162.04 per share (previous year: 378510 at CHF 117.53) and sold 187558 treasury shares at an average price of CHF 165.40 (previous year: 381680 at CHF 116.50).

6. Transactions with related parties

HBM Healthcare holds an investment in the Hatteras Venture Partners III fund, where Board member Robert A. Ingram serves as General Partner. For details on the investment commitment, paid-in capital and valuation of this investment, please refer to the overview of funds on page 15.

hbmhealthcare.com



SIX Swiss Exchange Ticker

Significant shareholders

Based on the notifications received by the Company, the following shareholders reported equity holdings in HBM Healthcare Investments Ltd of three percent or more as at 31 December 2018:

Shareholding

15–20% Nogra Pharma Invest S.à.r.l., Luxemburg

Fees

Management fee (paid quarterly): 0.75% of Company assets plus 0.75% of the Company's market capitalisation Performance fee (paid annually): 15% on increase in value above the high water mark High water mark (per share for all outstanding shares) for financial year 2018/2019: NAV of CHF 161.87

Board of Directors and Management

Hans Peter Hasler, Chairman
Prof. Dr Dr h.c. mult. Heinz Riesenhuber,
Vice Chairman
Mario G. Giuliani, Member
Dr Eduard E. Holdener, Member
Robert A. Ingram, Member
Dr Rudolf Lanz, Member
Dr Benedikt Suter, Secretary
Dr. Androac Wieki, Chief Executive Officer
Dr Andreas Wicki, Chief Executive Officer
Erwin Troxler, Chief Financial Officer

Investment Advisor

HBM Partners Ltd, Zug www.hbmpartners.com

Credits

Editorial HBM Healthcare Investments Ltd Concept and realisation Weber-Thedy Strategic Communication Design Küng Art Direction Layout Bader + Niederöst AG Copyright © 2019 HBM Healthcare Investments Ltd Published in English and German. The German version is binding in all matters of interpretation.

HBM Healthcare Investments Ltd Bundesplatz 1, 6300 Zug/Switzerland Phone +41 41 710 75 77 www.hbmhealthcare.com